Pharma mergers: FTC and DOJ to explore new ways of enforcing antitrust laws
Just when the pharma industry thought today’s $3 billion GSK buyout might kick off M&A season, the Department of Justice and the Federal Trade Commission said later in the afternoon they’re putting on a 2-day workshop in two weeks that will focus on “new approaches to enforcing the antitrust laws in the pharmaceutical industry.”
The virtual workshop will include a keynote from FTC commissioner Rebecca Kelly Slaughter, who has previously sought to block key pharma mergers and recently pulled together international partners from Canada, the UK and the EU, to identify concrete and actionable steps to review and update their analyses of pharma mergers. This workshop is the culmination of the work of this group of regulators, known collectively as the Multilateral Pharmaceutical Merger Task Force, the FTC said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
